Skip to main content
Erschienen in: Journal of Neurology 7/2015

01.07.2015 | Original Communication

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study

verfasst von: A. Siri, Clarisse Carra-Dalliere, X. Ayrignac, J. Pelletier, B. Audoin, S. Pittion-Vouyovitch, M. Debouverie, C. Lionnet, F. Viala, D. Sablot, D. Brassat, J.-C. Ouallet, A. Ruet, B. Brochet, L. Taillandier, L. Bauchet, N. Derache, G. Defer, P. Cabre, J. de Seze, C. Lebrun Frenay, M. Cohen, P. Labauge

Erschienen in: Journal of Neurology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Isolated tumefactive demyelinating lesion (TDL) is a rare disease and a challenging entity especially for the differential diagnosis, biopsy indications, and therapeutic decisions. Long-term evolution is not well known. The objective of the study is to describe clinical and MRI characteristics and long-term follow-up of patients with isolated TDL. We performed a retrospective study including patients (1) with one TDL radiologically defined by a ≥20 mm FLAIR hyperintensity involving the white matter associated with T1 hypointensity that enhanced after gadolinium injection and (2) without any other MS lesion on the first MRI. Tumor, abscess, or other inflammatory diseases (ADEM, Baló’s concentric sclerosis, systemic disease) were excluded. Sixteen patients (11 females/5 males) were included. The mean age of onset was 35.7 years (range 20–65). MRI disclosed supratentorial lesions with a mean size of 39.4 mm and usually mild edema/mass effect. Peripheral (mainly open-ring pattern) and central (mainly heterogeneous) enhancement were respectively seen in 9/16 and 11/16 patients. CSF study (n = 15) found oligoclonal bands (OCB) in seven. A cerebral biopsy was performed in 11 cases showing acute inflammatory demyelination. Thirteen patients were treated by pulse steroids with marked improvement in ten. At last clinical follow-up (mean 65.8 months, range 6–181), diagnosis was MS in 5 (31 %), isolated TDL in 10 (63 %) and one patient had a second TDL (6 %). Isolated tumefactive demyelinating lesions are a rare diagnostic entity. After a mean follow-up of 5 years, almost one-third became MS whereas most of the patients had no further event.
Literatur
1.
Zurück zum Zitat Poser S, Lüer W, Bruhn H, Frahm J, Brück Y, Felgenhauer K (1992) Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86:579–585CrossRefPubMed Poser S, Lüer W, Bruhn H, Frahm J, Brück Y, Felgenhauer K (1992) Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86:579–585CrossRefPubMed
2.
Zurück zum Zitat Hardy TA, Chataway J (2013) Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84:1047–1053CrossRefPubMed Hardy TA, Chataway J (2013) Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84:1047–1053CrossRefPubMed
3.
Zurück zum Zitat Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M (1991) Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180:467–474CrossRefPubMed Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M (1991) Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180:467–474CrossRefPubMed
4.
Zurück zum Zitat Kepes JJ (1993) Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 33:18–27CrossRefPubMed Kepes JJ (1993) Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 33:18–27CrossRefPubMed
5.
Zurück zum Zitat Zagzag D, Miller DC, Kleinman GM, Abati A, Donnenfeld H, Budzilovich GN (1993) Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol 17:537–545CrossRefPubMed Zagzag D, Miller DC, Kleinman GM, Abati A, Donnenfeld H, Budzilovich GN (1993) Demyelinating disease versus tumor in surgical neuropathology. Clues to a correct pathological diagnosis. Am J Surg Pathol 17:537–545CrossRefPubMed
6.
Zurück zum Zitat Annesley-Williams D, Farrell MA, Staunton H, Brett FM (2000) Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 59:477–489PubMed Annesley-Williams D, Farrell MA, Staunton H, Brett FM (2000) Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 59:477–489PubMed
7.
Zurück zum Zitat Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedCentralCrossRefPubMed Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Nagappa M, Taly AB, Sinha S, Bharath RD, Mahadevan A, Bindu PS et al (2013) Tumefactive demyelination: clinical imaging and follow-up observations in thirty-nine patients. Acta Neurol Scand 128:39–47CrossRefPubMed Nagappa M, Taly AB, Sinha S, Bharath RD, Mahadevan A, Bindu PS et al (2013) Tumefactive demyelination: clinical imaging and follow-up observations in thirty-nine patients. Acta Neurol Scand 128:39–47CrossRefPubMed
9.
Zurück zum Zitat Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302PubMedCentralCrossRefPubMed Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Giang DW, Poduri KR, Eskin TA, Ketonen LM, Friedman PA, Wang DD et al (1992) Multiple sclerosis masquerading as a mass lesion. Neuroradiology 34:150–154CrossRefPubMed Giang DW, Poduri KR, Eskin TA, Ketonen LM, Friedman PA, Wang DD et al (1992) Multiple sclerosis masquerading as a mass lesion. Neuroradiology 34:150–154CrossRefPubMed
11.
Zurück zum Zitat Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M et al (2012) Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 18:1448–1453CrossRefPubMed Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M et al (2012) Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 18:1448–1453CrossRefPubMed
13.
Zurück zum Zitat Yao J, Huang D, Gui Q, Chen X, Lou X, Wu L et al (2015) Clinical and radiological characteristics of 17 Chinese patients with pathology confirmed tumefactive demyelinating diseases: follow-up study. J Neurol Sci 348:153–159CrossRefPubMed Yao J, Huang D, Gui Q, Chen X, Lou X, Wu L et al (2015) Clinical and radiological characteristics of 17 Chinese patients with pathology confirmed tumefactive demyelinating diseases: follow-up study. J Neurol Sci 348:153–159CrossRefPubMed
14.
Zurück zum Zitat Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14:1157–1174PubMedCentralCrossRefPubMed Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14:1157–1174PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Kiriyama T, Kataoka H, Taoka T, Tonomura Y, Terashima M, Morikawa M et al (2011) Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21:e69–e77CrossRefPubMed Kiriyama T, Kataoka H, Taoka T, Tonomura Y, Terashima M, Morikawa M et al (2011) Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21:e69–e77CrossRefPubMed
16.
Zurück zum Zitat Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P (2000) Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 11(54):1427–1433CrossRef Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P (2000) Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 11(54):1427–1433CrossRef
17.
Zurück zum Zitat Koelblinger C, Fruehwald-Pallamar J, Kubin K, Wallner-Blazek M, van den Hauwe L, Macedo L (2013) Atypical idiopathic inflammatory demyelinating lesions (IIDL): conventional and diffusion-weighted MR imaging (DWI) findings in 42 cases. Eur J Radiol 82(11):1996–2004CrossRefPubMed Koelblinger C, Fruehwald-Pallamar J, Kubin K, Wallner-Blazek M, van den Hauwe L, Macedo L (2013) Atypical idiopathic inflammatory demyelinating lesions (IIDL): conventional and diffusion-weighted MR imaging (DWI) findings in 42 cases. Eur J Radiol 82(11):1996–2004CrossRefPubMed
18.
Zurück zum Zitat Selkirk SM, Shi J (2005) Relapsing-remitting tumefactive multiple sclerosis. Mult Scler 11:731–734CrossRefPubMed Selkirk SM, Shi J (2005) Relapsing-remitting tumefactive multiple sclerosis. Mult Scler 11:731–734CrossRefPubMed
19.
Zurück zum Zitat Haupts MR, Schimrigk SK, Brune N, Chan A, Ahle G, Hellwig K et al (2008) Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 255:1272–1273CrossRefPubMed Haupts MR, Schimrigk SK, Brune N, Chan A, Ahle G, Hellwig K et al (2008) Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 255:1272–1273CrossRefPubMed
20.
Zurück zum Zitat Dastgir J, DiMario FJ (2009) Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol 24:431–437CrossRefPubMed Dastgir J, DiMario FJ (2009) Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol 24:431–437CrossRefPubMed
Metadaten
Titel
Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study
verfasst von
A. Siri
Clarisse Carra-Dalliere
X. Ayrignac
J. Pelletier
B. Audoin
S. Pittion-Vouyovitch
M. Debouverie
C. Lionnet
F. Viala
D. Sablot
D. Brassat
J.-C. Ouallet
A. Ruet
B. Brochet
L. Taillandier
L. Bauchet
N. Derache
G. Defer
P. Cabre
J. de Seze
C. Lebrun Frenay
M. Cohen
P. Labauge
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 7/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7758-8

Weitere Artikel der Ausgabe 7/2015

Journal of Neurology 7/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.